BE2014C071I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C071I2 BE2014C071I2 BE2014C071C BE2014C071C BE2014C071I2 BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2 BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004174770 | 2004-06-11 | ||
| JP2004327111 | 2004-11-10 | ||
| US63059604P | 2004-11-23 | 2004-11-23 | |
| US11/150,792 US7378423B2 (en) | 2004-06-11 | 2005-06-10 | Pyrimidine compound and medical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2014C071I2 true BE2014C071I2 (fr) | 2024-10-08 |
Family
ID=35600249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2014C071C BE2014C071I2 (fr) | 2004-06-11 | 2014-11-28 |
Country Status (2)
| Country | Link |
|---|---|
| US (8) | US7378423B2 (fr) |
| BE (1) | BE2014C071I2 (fr) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
| US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| JP2007525165A (ja) | 2003-03-07 | 2007-09-06 | トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | タイプ１ライアノジン受容体に基づく方法 |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| WO2006091936A2 (fr) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Procedes permettant d'effectuer la synthese de xanthines a substitution cycloalkyle dissymetrique |
| US20090047278A1 (en) * | 2005-02-28 | 2009-02-19 | Eisai R & D Management Co., Ltd. | Novel Combinational Use of Sulfonamide Compound |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| WO2008058287A1 (fr) * | 2006-11-10 | 2008-05-15 | Syndax Pharmaceuticals, Inc. | Association de ligands de era+ et d'inhibiteurs de l'histone désacétylase dans le traitement du cancer |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| JP2010533714A (ja) * | 2007-07-16 | 2010-10-28 | ポニアード ファーマシューティカルズ， インコーポレイテッド | ピコプラチンのための経口製剤 |
| US20100298270A1 (en) * | 2007-07-23 | 2010-11-25 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| US20100267779A1 (en) * | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| WO2009049018A1 (fr) * | 2007-10-10 | 2009-04-16 | Syndax Pharmaceuticals, Inc. | Composés nouveaux et procédés pour les utiliser |
| US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| WO2009067453A1 (fr) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinaisons d'inhibiteurs de la hdac et d'inhibiteurs de protéasomes |
| AU2009210656A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
| RU2508110C2 (ru) * | 2008-07-11 | 2014-02-27 | Новартис Аг | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek |
| US8697685B2 (en) | 2008-11-20 | 2014-04-15 | Glaxosmithkline Llc | Chemical compounds |
| US8647067B2 (en) * | 2008-12-09 | 2014-02-11 | General Electric Company | Banked platform turbine blade |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| CA2755561A1 (fr) * | 2009-03-26 | 2010-09-30 | Mapi Pharma Limited | Procede de preparation d'alogliptine |
| WO2011038082A1 (fr) * | 2009-09-23 | 2011-03-31 | Glaxosmithkline Llc | Combinaison pharmaceutique |
| EP2480085B1 (fr) | 2009-09-23 | 2014-11-12 | GlaxoSmithKline LLC | Combinaison comprenant l'inhibiteur de MEK N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide et l'inhibiteur d'Akt N-{(1S)-2-amino-1-[(3-fluorophényl)-méthyl] éthyl}-5-chloro-4-(4-chloro-1-méthyl-1H-pyrazole-5-yl )-2-thiophène-carboxamide |
| BR112012006968A2 (pt) | 2009-09-28 | 2019-09-24 | Glaxosmithkline Llc | combinação |
| DK3560498T3 (da) | 2009-10-16 | 2022-11-14 | Novartis Ag | Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer |
| ES2578191T3 (es) * | 2009-11-17 | 2016-07-21 | Novartis Ag | Combinación |
| MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
| US9180129B2 (en) | 2010-05-21 | 2015-11-10 | Novartis Ag | Combination of lapatinib and trametinib |
| WO2012027438A1 (fr) | 2010-08-26 | 2012-03-01 | Glaxosmithkline Llc | Combinaison pharmaceutique d'un inhibiteur du vegfr et d'un nhibiteur de mek, utile pour traiter le cancer |
| EP2640390A4 (fr) * | 2010-11-17 | 2014-08-06 | Glaxosmithkline Ip No 2 Ltd | Procédés de traitement du cancer |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| WO2012088030A1 (fr) * | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Combinaison |
| MX2014002471A (es) | 2011-08-31 | 2014-03-27 | Novartis Ag | Combinaciones sinergicas de los inhibidores de p13k y mek. |
| UA114906C2 (uk) | 2012-03-14 | 2017-08-28 | Люпін Лімітед | Гетероциклільні сполуки як інгібітори мек |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| SI2884979T1 (sl) | 2012-08-17 | 2019-10-30 | Hoffmann La Roche | Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba |
| EP2911673A4 (fr) * | 2012-10-25 | 2016-05-18 | Novartis Ag | Combinaison |
| US20150328320A1 (en) * | 2012-11-30 | 2015-11-19 | Glaxosmithkline Llc | Novel Pharmaceutical Composition |
| KR20150103735A (ko) | 2013-01-09 | 2015-09-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 조합물 |
| US20140199728A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| UY35587A (es) | 2013-05-28 | 2014-12-31 | Glaxosmithkline Ip No 2 Ltd | Método de tratamiento del cáncer |
| HK1216231A1 (zh) | 2013-06-03 | 2016-10-28 | Novartis Ag | Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物 |
| WO2015056180A1 (fr) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Dérivés d'indoline utilisés comme inhibiteurs de perk |
| WO2015059677A1 (fr) | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Méthodes de traitement du cancer |
| BR112016011222A2 (pt) | 2013-12-12 | 2017-09-19 | Novartis Ag | Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer |
| EP3378952B1 (fr) | 2013-12-28 | 2020-02-05 | Guardant Health, Inc. | Procédés et systèmes de détection de variants génétiques |
| WO2015105822A1 (fr) * | 2014-01-07 | 2015-07-16 | Glaxosmithkline Llc | Procédé de traitement du cancer |
| EP2913048A1 (fr) | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Composition pharmaceutique comprenant de la trametinib |
| WO2016055935A1 (fr) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaison d'inhibiteur de déméthylase 1 spécifique à la lysine et d'agoniste de thrombopoïétine |
| WO2016059602A2 (fr) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Méthodes de traitement du cancer et compositions associées |
| WO2017037574A1 (fr) | 2015-08-28 | 2017-03-09 | Novartis Ag | Combinaisons de l'inhibiteur de cdk4/6 lee011 et de l'inhibiteur de mek1/2 trametinib, comprenant éventuellement en outre l'inhibiteur de pi3k byl719 pour traiter le cancer |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| US10861357B2 (en) * | 2015-11-13 | 2020-12-08 | Nike, Inc. | Athletic bib |
| RU2605400C1 (ru) * | 2015-11-13 | 2016-12-20 | ЗАО "Р-Фарм" | ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2 |
| WO2017098421A1 (fr) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Composés benzothiadiazine |
| WO2017153952A1 (fr) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de 5-sulfamoyl-2-hydroxybenzamide |
| KR101796684B1 (ko) * | 2016-05-19 | 2017-11-10 | 건국대학교 산학협력단 | 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법 |
| RU2627692C1 (ru) | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| TW201922721A (zh) | 2017-09-07 | 2019-06-16 | 英商葛蘭素史克智慧財產發展有限公司 | 化學化合物 |
| WO2019053617A1 (fr) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019180141A1 (fr) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinaisons de rogaratinib |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113226322A (zh) * | 2018-10-30 | 2021-08-06 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
| EP4342473A3 (fr) | 2018-11-30 | 2024-05-15 | GlaxoSmithKline Intellectual Property Development Limited | Composés utiles dans la thérapie du vih |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| US12221440B2 (en) * | 2019-02-06 | 2025-02-11 | Aurobindo Pharma Ltd | Process for the preparation of trametinib acetic acid solvate |
| JP7465945B2 (ja) | 2019-07-02 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | Ｂｅｔ阻害剤としてのヘテロ環式化合物 |
| MX2022001328A (es) * | 2019-07-30 | 2022-05-20 | Edvince Ab | Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia. |
| AU2020326612B2 (en) | 2019-08-02 | 2025-10-23 | Onehealthcompany, Inc. | Treatment of canine cancers |
| US12268692B2 (en) | 2020-04-10 | 2025-04-08 | Postsurgical Therapeutics, Inc. | Combinatorial targeted therapy methods |
| US20230266321A1 (en) * | 2020-06-25 | 2023-08-24 | Icahn School Of Medicine At Mount Sinai | Live cell engagement assay |
| US20250032494A1 (en) | 2021-12-06 | 2025-01-30 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| CN114853754B (zh) * | 2022-05-23 | 2023-04-18 | 云白药征武科技(上海)有限公司 | 一种硫代酰胺衍生物及其制备方法和应用 |
| AR129423A1 (es) | 2022-05-27 | 2024-08-21 | Viiv Healthcare Co | Compuestos útiles en la terapia contra el hiv |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3139432A (en) | 1963-06-24 | 1964-06-30 | Mead Johnson & Co | Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones |
| DE4035479A1 (de) | 1990-11-08 | 1992-05-14 | Basf Ag | Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione |
| WO2000035435A1 (fr) | 1998-12-15 | 2000-06-22 | Warner-Lambert Company | Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek |
| EP1143957A3 (fr) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Traitement de l'arthrite a l'aide d'inhibiteurs de la mek |
| IL144103A0 (en) | 1999-01-07 | 2002-05-23 | Warner Lambert Co | Antiviral method using mek inhibitors |
| EP1140062B1 (fr) | 1999-01-07 | 2005-04-06 | Warner-Lambert Company LLC | Traitement de l'asthme a l'aide d'inhibiteurs de mek |
| CN1365277A (zh) | 1999-07-16 | 2002-08-21 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| CA2416685C (fr) | 2000-07-19 | 2008-10-07 | Warner-Lambert Company | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| AU2001271067A1 (en) | 2000-07-19 | 2002-01-30 | Chugai Seiyaku Kabushiki Kaisha | Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound |
| US20040138285A1 (en) * | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US6825180B2 (en) | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| DE60303009T2 (de) | 2002-01-22 | 2006-07-13 | Warner-Lambert Co. Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
-
2005
- 2005-06-10 US US11/150,792 patent/US7378423B2/en active Active
-
2008
- 2008-03-21 US US12/053,133 patent/US20080312228A1/en not_active Abandoned
-
2009
- 2009-11-25 US US12/626,443 patent/US8835443B2/en active Active
-
2014
- 2014-08-07 US US14/454,404 patent/US20150183812A1/en not_active Abandoned
- 2014-11-28 BE BE2014C071C patent/BE2014C071I2/fr unknown
-
2016
- 2016-02-24 US US15/052,581 patent/US20170029418A1/en not_active Abandoned
-
2017
- 2017-10-27 US US15/795,973 patent/US20180273531A1/en not_active Abandoned
-
2019
- 2019-05-20 US US16/416,895 patent/US20200109139A1/en not_active Abandoned
-
2021
- 2021-12-08 US US17/545,664 patent/US20220380362A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200109139A1 (en) | 2020-04-09 |
| US8835443B2 (en) | 2014-09-16 |
| US20080312228A1 (en) | 2008-12-18 |
| US20180273531A1 (en) | 2018-09-27 |
| US20060014768A1 (en) | 2006-01-19 |
| US20170029418A1 (en) | 2017-02-02 |
| US20150183812A1 (en) | 2015-07-02 |
| US20100240613A1 (en) | 2010-09-23 |
| US20220380362A1 (en) | 2022-12-01 |
| US7378423B2 (en) | 2008-05-27 |